How we know
Every link on this study, and who decided it
The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.
Why Pembrolizumab is on this study
- No treatment in the record names it; a reading of the whole record found it given.
- Claude Opus 5.5 judged it the comparator: what is tested is compared with it. Nov 1, 2026, 8:22 AM UTC
- The role rule had no answer: no treatment entry names it.
- So Pembrolizumab's page lists this study under “As the comparator”.
Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.
Pembrolizumab
Made here1 judgment on this linkAll judgments on this study
| When | Link | Judge | Decision | State |
|---|---|---|---|---|
| Nov 1 | Pembrolizumabmade here | Claude Opus 5.5 | Comparator | Current |
| Nov 2 | Trastuzumabmade here | Claude Opus 5.5 | Comparator | Current |
| Nov 14 | Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma | Rule based · condition-kind rule | Not read | Current |
The rules, in plain words
“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.
How a condition link is counted
For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.
A decision on file for one study overrides it, with who made it and when.